← Back to Clinical Trials
Recruiting NCT07089524

NCT07089524 A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07089524
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Sepsis
Study Type OBSERVATIONAL
Enrollment 160 participants
Start Date 2024-09-11
Primary Completion 2025-09-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 160 participants in total. It began in 2024-09-11 with a primary completion date of 2025-09-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Aim of this study is to predict the prognostic values of Neutrophil/ Lymphocyte ratio and Lactate/Albumin ratio in the outcome of patients with sepsis and septic shock with lower respiratory tract infection, also to compare between them regarding sensitivity and specificity.

Eligibility Criteria

Inclusion Criteria: * Adults with lower respiratory tract infection * Confirmed septic patients (under the third international consensus definitions of sepsis and septic shock), * Admitted to intensive care unit. * Age (18-80) years. * Both genders. Exclusion Criteria: * Age: \< 18 years old, \> 80 years old * Patient refusal. * Pregnancy. * Malignancy. * Pathology that could affect serum albumin concentrations prior to ICU admission as Malnutrition * Nephrotic syndrome * Liver Cirrhosis * Intestinal resection surgeries

Contact & Investigator

Central Contact

Ahmed Gamal Ahmed, M.BB.CH,M.Sc

✉ ahmed_gamal@med.asu.edu.eg

📞 01141164417

Frequently Asked Questions

Who can join the NCT07089524 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07089524 currently recruiting?

Yes, NCT07089524 is actively recruiting participants. Contact the research team at ahmed_gamal@med.asu.edu.eg for enrollment information.

Where is the NCT07089524 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07089524 clinical trial?

NCT07089524 is sponsored by Ain Shams University. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology